{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+I&page=2", "query": { "intervention": "Cohort I", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+I&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T16:11:19.258Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04975958", "title": "Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumor" ], "interventions": [ { "name": "AN2025", "type": "DRUG" }, { "name": "AN0025", "type": "DRUG" }, { "name": "Atezolizumab 1200 mg in 20 ML Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adlai Nortye Biopharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2021-09-07", "completion_date": "2025-01-24", "has_results": false, "last_update_posted_date": "2025-06-22", "last_synced_at": "2026-09-27T16:11:19.258Z", "location_count": 5, "location_summary": "Aurora, Colorado • Lake Mary, Florida • New Brunswick, New Jersey + 2 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Lake Mary", "state": "Florida" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04975958" }, { "nct_id": "NCT05599048", "title": "Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "Hyperpolarized 13C-Pyruvate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging (MRI)", "type": "PROCEDURE" }, { "name": "13C,15N-Urea", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Robert Bok, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2022-12-15", "completion_date": "2027-01-31", "has_results": false, "last_update_posted_date": "2026-05-27", "last_synced_at": "2026-09-27T16:11:19.258Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05599048" }, { "nct_id": "NCT05065710", "title": "A Study of ZL-1211 in Patients With Advanced Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "ZL-1211", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zai Biopharmaceutical (Suzhou) Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2022-01-19", "completion_date": "2024-04-09", "has_results": false, "last_update_posted_date": "2024-09-03", "last_synced_at": "2026-09-27T16:11:19.258Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Lynwood, California • Indianapolis, Indiana + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Lynwood", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05065710" }, { "nct_id": "NCT01005797", "title": "Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cancer", "Non Small Cell Lung Cancer (NSCLC)", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "Panobinostat (LBH589), Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2009-11", "completion_date": "2017-01", "has_results": false, "last_update_posted_date": "2017-03-03", "last_synced_at": "2026-09-27T16:11:19.258Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01005797" }, { "nct_id": "NCT00821652", "title": "Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors" ], "interventions": [ { "name": "NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod", "type": "DRUG" }, { "name": "NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nina Bhardwaj", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2009-02", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-09-27T16:11:19.258Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00821652" }, { "nct_id": "NCT01397708", "title": "Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "INXN-2001", "type": "BIOLOGICAL" }, { "name": "INXN-1001", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Alaunos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2011-08", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-09-27T16:11:19.258Z", "location_count": 9, "location_summary": "Los Angeles, California • Park Ridge, Illinois • Goshen, Indiana + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01397708" }, { "nct_id": "NCT06491550", "title": "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "AZD4144- Part A", "type": "DRUG" }, { "name": "Placebo- Part A", "type": "DRUG" }, { "name": "AZD4144- Part B", "type": "DRUG" }, { "name": "Placebo- Part B", "type": "DRUG" }, { "name": "Rosuvastatin and Furosemide- Part C", "type": "DRUG" }, { "name": "Rosuvastatin, Furosemide, and AZD4144 Part C", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 91, "start_date": "2024-07-15", "completion_date": "2025-06-11", "has_results": false, "last_update_posted_date": "2025-07-04", "last_synced_at": "2026-09-27T16:11:19.258Z", "location_count": 2, "location_summary": "Glendale, California • Brooklyn, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Brooklyn", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06491550" }, { "nct_id": "NCT05068674", "title": "Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Ischemic Left Ventricular Dysfunction" ], "interventions": [ { "name": "Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells", "type": "DRUG" }, { "name": "Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells", "type": "DRUG" }, { "name": "Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Joseph C. Wu", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "21 Years to 80 Years" }, "enrollment_count": 18, "start_date": "2022-03-22", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2025-09-29", "last_synced_at": "2026-09-27T16:11:19.258Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05068674" }, { "nct_id": "NCT02140255", "title": "Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Nucleoside Reverse Transcriptase Inhibitors (NRTIs)", "type": "DRUG" }, { "name": "Nevirapine (NVP)", "type": "DRUG" }, { "name": "Lopinavir/Ritonavir (LPV/r)", "type": "DRUG" }, { "name": "Raltegravir (RAL)", "type": "DRUG" }, { "name": "VRC01", "type": "DRUG" }, { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "VRC07-523LS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "48 Hours", "sex": "ALL", "summary": "Up to 48 Hours" }, "enrollment_count": 1120, "start_date": "2015-01-23", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-27T16:11:19.258Z", "location_count": 21, "location_summary": "La Jolla, California • Los Angeles, California • Aurora, Colorado + 13 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02140255" }, { "nct_id": "NCT07285668", "title": "Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "Allogeneic donor TCRαβ+/CD19+ cell-depleted peripheral blood mononuclear cells", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 38, "start_date": "2026-02-26", "completion_date": "2031-02", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-27T16:11:19.258Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07285668" } ] }